RxDoctor Payments Data

Suhel Ahmed, MD

Internal Medicine · Hackensack, NJNPI 1801042072

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,158 of the $82,386 with a category attached, or 77.9%. Novo Nordisk accounts for 76.2% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $38,722, more than ten times the $1,533 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$82,386in general payments, 2019–2025

Across 607 payments — averaging $135.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$63K
  • Intra-sana Laboratories$11K
  • Pfizer$745
  • Boston Scientific$698
  • AbbVie$601
  • Exact Sciences$385
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$64,15878%
  • Travel & lodging$3,5984%
  • Food & beverage$14,63018%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk218$62,762
Intra-sana Laboratories26$11,431
Pfizer49$745
Boston Scientific7$698
AbbVie(2 entities)53$601
Exact Sciences12$385
AstraZeneca(2 entities)17$366
GSK24$358
Boehringer Ingelheim7$311
Bayer10$293
Daiichi Sankyo Inc.15$247
Medtronic(2 entities)3$228
Biosense Webster, Inc.3$226
Abbott8$217
Lilly USA, LLC13$217
Johnson & Johnson13$199
Gilead14$190
Axsome Therapeutics, Inc.5$171
Asensus Surgical, Inc.3$166
Dexcom, Inc.3$166
Corcept Therapeutics3$161
Biotronik NRO, Inc.3$151
Amgen(2 entities)11$149
Abiomed1$148
Qapel Medical Inc1$147
Novartis2$141
Lexicon Pharmaceuticals, Inc.1$125
Currax Pharmaceuticals LLC7$111
Astellas Pharma US Inc5$104
Amneal Pharmaceuticals LLC1$100
Amarin Pharma, Inc.7$92
Vivus LLC6$89
Endo Pharmaceuticals Inc.5$72
Philips North America LLC3$62
Merck4$60
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$59
Biohaven Pharmaceuticals, Inc.4$58
Arbor Pharmaceuticals, Inc.4$54
Otsuka America Pharmaceutical, Inc.4$53
Phadia US Inc.3$48
Biohaven Pharmaceutical Holding Company Ltd.3$44
Viiv Healthcare Company2$37
Kerecis Limited1$36
Intuity Medical Inc2$36
Insightec,inc1$28
Nalpropion Pharmaceuticals LLC2$25
Inspire Medical Systems, Inc.1$21
Phathom Pharmaceuticals, Inc.1$19
Bausch Health US, LLC1$18
Invivyd Inc1$18
3b Medical, Inc.1$18
Mannkind Corporation1$16
Rhythm Pharmaceuticals, Inc.1$16
Azurity Pharmaceuticals, Inc.1$15
Takeda Pharmaceuticals U.S.A., Inc.1$14
Xeris Pharmaceuticals, Inc.1$14
CSL Behring1$13
Sanofi-aventis U.S. LLC1$13
Kowa Pharmaceuticals America, Inc.1$13
Echosens North America, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,386 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$272,269
Medicare patients
436
Services billed
3,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$137,597
WegovySemaglutide69$92,017
MounjaroTirzepatide70$77,795
EliquisApixaban12$20,766
TrulicityDulaglutide18$17,361
FarxigaDapagliflozin Propanediol19$16,972
JardianceEmpagliflozin19$15,384
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,636
Atorvastatin Calcium119$1,364
SynthroidLevothyroxine Sodium18$1,340
Pantoprazole Sodium87$1,182
Levothyroxine Sodium103$1,084
Topiramate97$865
Bupropion XlBupropion Hcl22$713
Losartan Potassium79$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$62,762$229,614170 claims
Lilly USA, LLCMounjaro, Trulicity$217$95,15588 claims
PfizerEliquis$745$20,76612 claims
AstraZenecaFarxiga$366$16,97219 claims
Boehringer IngelheimJardiance$311$15,38419 claims
AbbVieSynthroid$601$1,34018 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$100$1,084103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →